<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000840.v1.p1" parentStudy="phs000840.v1.p1" createDate="2014-11-21" modDate="2016-08-10">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigators</td><td>David Altshuler</td><td>Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, 			MA, USA</td></tr>
		<tr><td>Principal Investigators</td><td>Michael Boehnke</td><td>University of Michigan, Ann Arbor, MI, USA</td></tr>
		<tr><td>Principal Investigators</td><td>Mark McCarthy</td><td>Wellcome Trust Centre for Human Genetics, Oxford, UK</td></tr>
		<tr><td>Principal Investigators</td><td>Jose Florez</td><td>Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA; Massachusetts General Hospital, Boston, MA, USA</td></tr>
		<tr><td>Co-Investigators</td><td>Gon&#231;alo Abecasis</td><td>University of Michigan, Ann Arbor, MI, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>GoT2D</StudyNameEntrez>
	<StudyNameReportPage>The Genetics of Type 2 Diabetes Consortium (GoT2D): Low-Pass Sequencing and High-Density SNP Genotyping for Type 2 Diabetes</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case-Control</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>The Genetics of Type 2 Diabetes Consortium (GoT2D) is a collaboration between the University of Michigan, the Broad Institute and the Wellcome Trust Centre for Human Genetics. The overall aim is to extend upon recent efforts, such as genome-wide association studies (GWAS) and large scale meta-analyses. While they have proved successful at mapping genomic loci that influence human diseases, like type 2 diabetes, much of the heritability remains unexplained. In this study, we use next generation sequencing and genotyping technologies to query for lower frequency variants in the human genome. Thereby, allowing a deeper characterization of the spectrum of alleles associated with type 2 diabetes risk, and a better assessment of the genes that play a role in the etiology of type 2 diabetes development. We studied 1,326 T2D cases and 1,331 normoglycemic controls from Northern and Central Europe (Sweden, Finland, UK, and Germany). To efficiently characterize the entire genome sequence of each individual, we performed low-coverage (~5x) whole-genome sequencing, augmented by deep coverage (~100x) sequencing of the exome (Fuchsberger et al, 2016), and dense (2.5M) single nucleotide polymorphism (SNP) genotyping using the HumanOmni2.5 array. The data deposited in dbGaP will include all the Swedish, Finnish, and UK samples, but the German data will be deposited in the European Genome-phenome Archive (<a href="https://www.ebi.ac.uk/ega/home">EGA</a>), by virtue of the project specific funding requirements.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>We selected 1425 type 2 diabetes (T2D) and 1425 normoglycemic controls from Northern and Central Europe (2,000 from Sweden and Finland, 650 from the UK, and 200 from Germany). Controls were defined to be of normal glucose tolerance. We preferentially sampled early onset, lean, and/or familial T2D cases and overweight controls with low fasting glucose levels. After quality control filters, we studied for analysis, cases 1,171 T2D cases and 1,177 normoglycemic controls.</p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="27398621"/>
		</Publication>
		<Publication>
			<Pubmed pmid="25625282"/>
		</Publication>
		<Publication>
			<Pubmed pmid="24584071"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Type 2 Diabetes Mellitus"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigators">
			<AttName>David Altshuler</AttName>
			<Institution>Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, 			MA, USA</Institution>
		</Header>
		<Header title="Principal Investigators">
			<AttName>Michael Boehnke</AttName>
			<Institution>University of Michigan, Ann Arbor, MI, USA</Institution>
		</Header>
		<Header title="Principal Investigators">
			<AttName>Mark McCarthy</AttName>
			<Institution>Wellcome Trust Centre for Human Genetics, Oxford, UK</Institution>
		</Header>
		<Header title="Principal Investigators">
			<AttName>Jose Florez</AttName>
			<Institution>Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA; Massachusetts General Hospital, Boston, MA, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Gon&#231;alo Abecasis</AttName>
			<Institution>University of Michigan, Ann Arbor, MI, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Leif Groop</AttName>
			<Institution>Malm&#246; University, Malm&#246;, Sweden</Institution>
		</Header>
		<Header title="Sequencing Institute">
			<AttName>The Broad Institute of Harvard and MIT</AttName>
			<Institution>Cambridge, MA, USA</Institution>
		</Header>
		<Header title="Funding Sources">
			<AttName>1RC2DK088389-01: Low-Pass Sequencing and High-Density SNP Genotyping for Type 2 Diabetes</AttName>
			<Institution>National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Sources">
			<AttName>U54HG003067: Large-Scale Sequencing and Analysis of Genomes</AttName>
			<Institution>National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Sources">
			<AttName>Wellcome Grant Numbers: 064890, 083948, 085475, 086596, 090367, 090532, 092447, 095101, 095552, 098017, 098381</AttName>
			<Institution>Wellcome Trust, London, UK</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<StudyURLs>
		<Url name="T2D-GENES" url="http://t2d-genes.sph.umich.edu/"/>
	</StudyURLs>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="DS-T2D-IRB-RD" longName="Disease-Specific (Type 2 Diabetes, IRB, RD)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NIDDK</DacName>
      <DacFullName>NIDDK Central Repository GWAS Data Access Committee</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000840.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>yes</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000840.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000840.v1.p1" FileName=""/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>Disease-Specific (Type 2 Diabetes, IRB, RD)</ConsentName>
        <ConsentAbbrev>DS-T2D-IRB-RD</ConsentAbbrev>
        <UseLimitation>Use of the data must be related to Type 2 Diabetes and related disorders.
Requestor must provide documentation of local IRB approval.</UseLimitation>
        <IrbRequired>Yes</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
